Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies

BACKGROUND: Atopic dermatitis is a chronic inflammatory skin disease that can negatively impact work productivity and daily activities. Ruxolitinib cream, a Janus kinase inhibitor, demonstrated efficacy and safety in patients with atopic dermatitis in two phase III studies (TRuE-AD1 and TRuE-AD2). O...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloudek, Lisa, Eichenfield, Lawrence F., Silverberg, Jonathan I., Joish, Vijay N., Lofland, Jennifer H., Sun, Kang, Augustin, Matthias, Migliaccio-Walle, Kristen, Sullivan, Sean D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870821/
https://www.ncbi.nlm.nih.gov/pubmed/36264430
http://dx.doi.org/10.1007/s40257-022-00734-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870821/
https://www.ncbi.nlm.nih.gov/pubmed/36264430
http://dx.doi.org/10.1007/s40257-022-00734-8

Ejemplares similares